n CME : Your SA Journal of CPD - Asthma : second-line therapies : main article

Volume 26, Issue 4
  • ISSN : 0256-2170



  • Asthma is an inflammatory condition of the airway.
  • The inflammation is responsible for the manifestations of asthma, namely the symptoms, the airflow limitation and the airway hyperresponsiveness.
  • The majority of asthmatics are treated with a controller medication of which the inhaled corticosteroids (ICS) are the mainstay of therapy.
  • In patients not controlled on ICS alone, it is recommended that an additional controller medication is added, rather than simply increasing the ICS dose, and the long-acting beta-agonists are the preferred option.
  • Leukotriene receptor antagonists (LTRAs) are suitable options that are given orally
  • LTRAs appear to be particularly useful for the treatment of asthma in children, for asthmatic patients with allergic rhinitis, for the treatment of exercise-induced asthma and for aspirin-induced asthma.
  • Sustained release theophylline is an alternative additional controller therapy, which although very cheap, is associated with low efficacy and a high frequency of side-effects.
  • Chromones have limited value in the long-term management of asthma.
  • Anti-immunoglobulin E therapy is the most recently introduced therapy which is recommended for use as a second-line agent in patients with moderate to severe allergic asthma not controlled on standard recommended therapy.
  • For reliever therapy, the primary bronchodilators are the short-acting beta-agonists (SABA), although anticholinergic agents may be suitable for older adults, for those intolerant of SABA, and for patients with nocturnal or intrinsic asthma.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error